United Therapeutics (NASDAQ:UTHR – Get Free Report) issued its earnings results on Wednesday. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54, Briefing.com reports. The business had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company’s quarterly revenue was up 33.7% on a year-over-year basis. During the same period in the previous year, the firm posted $4.86 EPS.
United Therapeutics Price Performance
Shares of NASDAQ:UTHR traded up $3.96 during midday trading on Thursday, reaching $259.10. 427,483 shares of the company’s stock were exchanged, compared to its average volume of 452,315. The company’s 50 day simple moving average is $235.34 and its two-hundred day simple moving average is $229.00. The firm has a market capitalization of $11.50 billion, a PE ratio of 13.06 and a beta of 0.54. United Therapeutics has a 12 month low of $204.44 and a 12 month high of $261.54. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41.
Insider Activity at United Therapeutics
In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $215.31, for a total value of $1,291,860.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $7,880,130.69. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $215.31, for a total transaction of $1,291,860.00. Following the completion of the sale, the executive vice president now owns 36,599 shares in the company, valued at approximately $7,880,130.69. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Christopher Patusky sold 1,680 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $224.00, for a total transaction of $376,320.00. Following the transaction, the director now owns 4 shares of the company’s stock, valued at approximately $896. The disclosure for this sale can be found here. Insiders sold 138,190 shares of company stock valued at $32,643,561 in the last ninety days. Insiders own 12.50% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Research Report on UTHR
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
See Also
- Five stocks we like better than United Therapeutics
- How to Use Stock Screeners to Find Stocks
- Meta Stock: 3 Reasons This Stumble Is a Golden Buying Opportunity
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Staples Stocks to Cushion Lower Consumer Sentiment
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Zillow’s Earnings Dip: An Opportunity for Visionaries
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.